Alcobra Ltd. (NASDAQ:ADHD) shares were down 3.2% during trading on Thursday . The company traded as low as $4.76 and last traded at $4.84, with a volume of 72,278 shares trading hands. The stock had previously closed at $5.00.

A number of research analysts have commented on ADHD shares. Barclays PLC started coverage on shares of Alcobra in a research note on Monday, August 1st. They issued an “equal weight” rating and a $8.00 price objective on the stock. Zacks Investment Research lowered shares of Alcobra from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Canaccord Genuity assumed coverage on shares of Alcobra in a research note on Tuesday, June 7th. They set a “buy” rating on the stock. Roth Capital reiterated a “buy” rating and set a $12.00 price target on shares of Alcobra in a research note on Tuesday, June 21st. Finally, Cantor Fitzgerald assumed coverage on shares of Alcobra in a research note on Tuesday, June 7th. They set a “buy” rating and a $16.00 price target on the stock. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Alcobra has a consensus rating of “Buy” and a consensus price target of $10.25.

The company’s market cap is $133.40 million. The company has a 50 day moving average price of $4.40 and a 200-day moving average price of $4.57.

Alcobra (NASDAQ:ADHD) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.04. On average, analysts forecast that Alcobra Ltd. will post ($0.97) EPS for the current year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.